Digital Integration Key Theme for ATW 2026

- The cell and gene therapy market is projected to grow from $22.98 billion in 2026 to $71.38 billion by 2032, demonstrating a compound annual growth rate (CAGR) of 20.39%. Another forecast predicts the market will reach $26.21 billion in 2026, growing to $60.58 billion in 2030 at a 23.3% CAGR. A third analysis suggests the market could reach $33.5 billion in 2026 and grow to $232.22 billion by 2035, reflecting a 24% CAGR. - A major challenge in viral vector manufacturing is the transition from small-scale 2D adherent cell cultures to large-scale 3D suspension systems in single-use bioreactors, a necessary step to meet commercial demand and reduce costs. Overcoming technical hurdles in downstream processing is also critical, as current methods can result in the loss of up to half of the viral vectors produced. - Digital twins are emerging as a key technology for optimizing bioprocesses, allowing for predictive modeling and real-time monitoring to improve process robustness and accelerate development timelines. These virtual replicas of physical processes can be used to simulate production outcomes, de-risk technology transfer, and enable more stable operations through model predictive control. Projects like the Fraunhofer Lighthouse Project RNAuto are exploring digital twins to document process data and ensure consistent product quality in allogeneic cell expansion. - The biotech funding climate has been challenging, with a significant drop in public funding in 2025 creating a difficult environment for startups. While venture capital has shown some signs of recovery, investment has consolidated into fewer, larger "mega-rounds" for less risky, clinical-stage assets. This has forced many early-stage companies to conserve cash and seek alternative financing, such as partnerships with larger pharmaceutical firms. - The CDMO market for cell and gene therapies is rapidly expanding to meet rising demand, with its value projected to grow from USD 4.31 billion in 2024 to USD 27.12 billion by 2033. This growth is driven by the increasing number of therapies in clinical trials and the need for specialized manufacturing expertise that many biotech startups lack. The sector is also seeing significant consolidation, with large CDMOs acquiring smaller firms to expand their technical capabilities. - There is a critical need for standardization in analytical methods to ensure the quality and consistency of cell and gene therapy products. Variability in biological assays and the complexity of the therapies themselves present significant challenges for analytical development. Recent studies have highlighted discrepancies between commonly used measurement techniques for AAV vectors, underscoring the need for further development and standardization of these methods. - Artificial intelligence and machine learning are being increasingly applied to accelerate AAV vector engineering, helping to optimize capsid design for improved tissue targeting and reduced immunogenicity. These technologies can analyze large datasets from high-throughput screening to predict vector performance, potentially reducing development time and manufacturing costs. Machine learning models like Fit4Function are being developed to identify AAVs with multiple desirable traits for therapeutic use. - For the first time, the Asia-Pacific region, led by China, surpassed North America in the number of cell and gene therapy clinical trials in 2025. This global shift is accelerating innovation, with the European Union also implementing initiatives like the Biotech Act to foster development through incentives and funding. The global expansion of early-phase trials requires adaptive strategies to meet diverse regional regulatory requirements.